Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.
Public ClinicalTrials.gov record NCT00195702. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Rheumatoid Arthritis Patients Currently Receiving Treatment With Methotrexate
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study was to assess the safety, immunogenicity, and clinical efficacy of adalimumab compared with placebo (during double-blind phase) and to to evaluate the long-term safety and maintenance of efficacy following repeated administration of adalimumab (during open-label extension phase) in patients with persistently active rheumatoid arthritis who were receiving concurrent methotrexate therapy.
Study identification
- NCT ID
- NCT00195702
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 619 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2000
- Primary completion
- Aug 31, 2002
- Completion
- Jul 31, 2010
- Last update posted
- Aug 25, 2011
2000 – 2010
United States locations
- U.S. sites
- 76
- U.S. states
- 30
- U.S. cities
- 67
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site Ref # / Investigator 424 | Huntsville | Alabama | 35801 | — |
| Site Ref # / Investigator 2510 | Mobile | Alabama | 36608 | — |
| Site Ref # / Investigator 60729 | Phoenix | Arizona | 85012 | — |
| Site Ref # / Investigator 725 | Scottsdale | Arizona | 85260 | — |
| Site Ref # / Investigator 60736 | Anaheim | California | 92801 | — |
| Site Ref # / Investigator 360 | Escondido | California | 92025 | — |
| Site Ref # / Investigator 714 | La Jolla | California | 92037-0943 | — |
| Site Ref # / Investigator 469 | La Jolla | California | 92037 | — |
| Site Ref # / Investigator 419 | Palm Desert | California | 92260 | — |
| Site Ref # / Investigator 492 | San Jose | California | 95126 | — |
| Site Ref # / Investigator 60734 | San Louis Obispo | California | 93405 | — |
| Site Ref # / Investigator 60739 | Van Nuys | California | 91405 | — |
| Site Ref # / Investigator 712 | Danbury | Connecticut | 06810 | — |
| Site Ref # / Investigator 710 | Aventura | Florida | 33180 | — |
| Site Ref # / Investigator 498 | Dunedin | Florida | 34698 | — |
| Site Ref # / Investigator 499 | Orlando | Florida | 32806 | — |
| Site Ref # / Investigator 729 | Tampa | Florida | 33614 | — |
| Site Ref # / Investigator 463 | Zephyrhills | Florida | 33542 | — |
| Site Ref # / Investigator 2436 | Boise | Idaho | 83704 | — |
| Site Ref # / Investigator 485 | Idaho Falls | Idaho | 83404 | — |
| Site Ref # / Investigator 60732 | Chicago | Illinois | 60611 | — |
| Site Ref # / Investigator 726 | Springfield | Illinois | 62704 | — |
| Site Ref # / Investigator 2506 | Indianapolis | Indiana | 46260 | — |
| Site Ref # / Investigator 732 | South Bend | Indiana | 46601 | — |
| Site Ref # / Investigator 60730 | Shawnee Mission | Kansas | 66216 | — |
| Site Ref # / Investigator 467 | Wichita | Kansas | 67203 | — |
| Site Ref # / Investigator 494 | Wichita | Kansas | 67208 | — |
| Site Ref # / Investigator 491 | Lexington | Kentucky | 40509 | — |
| Site Ref # / Investigator 2508 | Portland | Maine | 04102 | — |
| Site Ref # / Investigator 392 | Baltimore | Maryland | 21239 | — |
| Site Ref # / Investigator 354 | Cumberland | Maryland | 21502 | — |
| Site Ref # / Investigator 730 | Wheaton | Maryland | 20902 | — |
| Site Ref # / Investigator 465 | Burlington | Massachusetts | 01805 | — |
| Site Ref # / Investigator 2512 | Worcester | Massachusetts | 01610 | — |
| Site Ref # / Investigator 471 | Grand Rapids | Michigan | 49506 | — |
| Site Ref # / Investigator 473 | Kalamazoo | Michigan | 49009 | — |
| Site Ref # / Investigator 731 | Kansas City | Missouri | 64114 | — |
| Site Ref # / Investigator 502 | St Louis | Missouri | 63110 | — |
| Site Ref # / Investigator 482 | St Louis | Missouri | 63128 | — |
| Site Ref # / Investigator 371 | St Louis | Missouri | 63141 | — |
| Site Ref # / Investigator 487 | Omaha | Nebraska | 68114 | — |
| Site Ref # / Investigator 353 | Concord | New Hampshire | 03301 | — |
| Site Ref # / Investigator 364 | Dover | New Hampshire | 03820 | — |
| Site Ref # / Investigator 60726 | Mercerville | New Jersey | 08619 | — |
| Site Ref # / Investigator 358 | Voorhees Township | New Jersey | 08043 | — |
| Site Ref # / Investigator 483 | Rochester | New York | 14609 | — |
| Site Ref # / Investigator 512 | Durham | North Carolina | 27704 | — |
| Site Ref # / Investigator 340 | Greensboro | North Carolina | 27408 | — |
| Site Ref # / Investigator 461 | Raleigh | North Carolina | 27609 | — |
| Site Ref # / Investigator 500 | Raleigh | North Carolina | 27609 | — |
| Site Ref # / Investigator 60731 | Raleigh | North Carolina | 27612 | — |
| Site Ref # / Investigator 60737 | Salisbury | North Carolina | 28144 | — |
| Site Ref # / Investigator 456 | Mayfield Village | Ohio | 44143 | — |
| Site Ref # / Investigator 470 | Oklahoma City | Oklahoma | 73112 | — |
| Site Ref # / Investigator 60723 | Oklahoma City | Oklahoma | 73112 | — |
| Site Ref # / Investigator 422 | Eugene | Oregon | 97401 | — |
| Site Ref # / Investigator 60735 | Colmar | Pennsylvania | 18915-9671 | — |
| Site Ref # / Investigator 2507 | Duncansville | Pennsylvania | 16635 | — |
| Site Ref # / Investigator 717 | East Norriton | Pennsylvania | 19401 | — |
| Site Ref # / Investigator 352 | Mechanicsburg | Pennsylvania | 17055 | — |
| Site Ref # / Investigator 480 | Wexford | Pennsylvania | 15090 | — |
| Site Ref # / Investigator 2511 | Wyomissing | Pennsylvania | 19610 | — |
| Site Ref # / Investigator 60724 | Wyomissing | Pennsylvania | 19610 | — |
| Site Ref # / Investigator 718 | Charleston | South Carolina | 29406 | — |
| Site Ref # / Investigator 460 | Memphis | Tennessee | 38119 | — |
| Site Ref # / Investigator 462 | Nashville | Tennessee | 37205 | — |
| Site Ref # / Investigator 716 | Austin | Texas | 78705 | — |
| Site Ref # / Investigator 60728 | Galveston | Texas | 77555-0759 | — |
| Site Ref # / Investigator 2509 | Houston | Texas | 77074 | — |
| Site Ref # / Investigator 510 | Houston | Texas | 77074 | — |
| Site Ref # / Investigator 60725 | Falls Church | Virginia | 22044 | — |
| Site Ref # / Investigator 711 | Richmond | Virginia | 23219 | — |
| Site Ref # / Investigator 509 | Seattle | Washington | 98166-2967 | — |
| Site Ref # / Investigator 356 | Spokane | Washington | 99204 | — |
| Site Ref # / Investigator 464 | Tacoma | Washington | 98405 | — |
| Site Ref # / Investigator 60738 | Kenosha | Wisconsin | 53142 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00195702, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 25, 2011 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00195702 live on ClinicalTrials.gov.